 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.98 | 0.05 (0.11%)
| | NVS | $52.8 | 0.22 (0.42%)
| | SNY | $36.7 | -0.35 (-0.94%)
| | GSK | $40.52 | 0.06 (0.15%)
|
|
|
|
|
|
The purpose of Cancer News is to provide summaries of new treatment strategies as they are discovered and reported by cancer physicians around the world.
Original news summaries from peer-reviewed journals and
oncology meetings are provided daily.
 |
 News by Cancer Type |
 |
|
| We have categorized our cancer news articles by disease type.
Please select a topic from the drop down list below for more information on
that topic.
|
 |
|
|
 |
|
 |
| Latest Cancer News |
|
|
Vaccine Against HPV-16 Effective for Vulvar Intraepithelial Neoplasia (11/6/2009)
Researchers from the Netherlands have reported that vaccination with synthetic long-peptides against human papillomavirus (HPV)-16 was effective in treating vulvar intraepithelial neoplasia (VIN). The details of this study were published in the November 5, 2009 issue of the New England Journal of Medicine.
Small HER2-positive Breast Cancers Have a Higher Risk of Recurrence (11/6/2009)
Researchers from the M. D. Anderson Cancer Center and the University of Milan, Italy, have reported that women with Stage T1a,b, N0M0 HER2-positive breast cancers have a have a high recurrence rate without the administration of adjuvant chemotherapy or Herceptin® (trastuzumab). These data suggest that these women should be treated with Herceptin®-based adjuvant chemotherapy. The details of these two studies appeared in early online publications on November 2, 2009 in the Journal of Clinical Oncology.
Alcohol May Reduce Risk of Thyroid Cancer (11/6/2009)
Researchers affiliated with the NIH-AARP Diet and Health Study have reported that alcohol intake may reduce the risk of thyroid cancer. The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.
Continuous Daily Sutent® Palliative in Patients with Relapsed or Refractory Advanced NSCLC (11/5/2009)
Researchers from several U.S. and Spanish medical centers have reported that single-agent daily Sutent® (sunitinib) was associated with a 25% disease control rate in patients with previously treated advanced non–small cell lung cancer (NSCLC). The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.
Dose-dense Chemotherapy for Disseminated Thymoma Reported (11/5/2009)
Researchers from Japan have reported that dose-dense chemotherapy is effective for the treatment of patients with Stage IV thymoma. The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.
Childhood Cancer Survivors at Risk for Thyroid Cancer (11/5/2009)
Researchers from the UK have reported that survivors of childhood cancer are 18 times more likely to develop thyroid cancer than the general population. The details of this study appeared in the November 15, 2009 issue of the International Journal of Cancer.
Rapamune™ May Improve Responses to Gleevec® in Patients with Chordoma (11/4/2009)
Researchers from Italy have reported that the addition of Rapamune® (sirolimus, rapamycin) to Gleevec® (imatinib) may improve disease control in patients with chordoma resistant to Gleevec. The details of this study appeared in the November 2009 issue of the Annals of Oncology.
Low-dose Interferon-alfa Does Not Improve Outcomes of Patients with Renal Cell Carcinoma Receiving Nexavar® (11/4/2009)
Researchers from the M. D. Anderson Cancer Center have reported that the addition of low-dose interferon-alfa (IFN) to Nexavar® (sorafenib) did not improve survivals of patients with advanced renal cell carcinoma (RCC). The details of this study were published early online in Cancer on October 27. 2009.
Anticonvulsants May Improve Survival of Patients with Glioblastoma (11/4/2009)
Researchers from the Mayo Clinic have reported that patients with glioblastoma who are receiving enzyme-inducing anticonvulsant (EIAC) drugs may have improved outcomes compared with similar patients with glioblastoma not taking such drugs. The details of this study appeared in the October 13, 2009 issue of Neurology.
Smoking Cessation Leads to Reduction in Risk of Head and Neck Cancer (11/3/2009)
Researchers involved in the International Head and Neck Cancer Epidemiology Consortium have reported that smoking cessation for one to four years resulted in a 30% reduction in the risk of head and neck cancer. A benefit of cessation of alcohol drinking, however, was not observed until after 20 years or more. The details of this study appeared in an early online publication in the International Journal of Epidemiology on October 5, 2009.
Risk of Pancreatic Cancer in Families with Lynch Syndrome Defined (11/3/2009)
Researchers from several U.S. medical centers have reported that patients with Lynch syndrome have an 8.6-fold increase in the risk of pancreatic cancer compared with the general population. The details of this study appeared in the October 28, 2009 issue of the Journal of the American Medical Association.
New Analysis Suggests Decreased Mortality from Hormone Replacement Therapy in Younger Postmenopausal Women (11/3/2009)
Researchers from Stanford University, McMaster University, California Institute of Technology, and Cornell University have reported that hormone replacement therapy (HRT) may reduce mortality by 28% in younger postmenopausal women. The details of this study appeared in the November 2009 issue of the American Journal of Medicine.
Arzerra™ Approved for Refractory Chronic Lymphocytic Leukemia (11/2/2009)
The targeted therapy Arzerra™ (ofatumumab) has been granted accelerated approval by the U.S. Food and Drug Administration for treatment of patients with chronic lymphocytic leukemia (CLL) that is refractory to Fludara® (fludarabine) and Campath® (alemtuzumab).
Addition of Xeloda® to Gemzar® Improves Outcomes in Pancreatic Cancer (11/2/2009)
Researchers affiliated with the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) have reported that the addition of Xeloda® (capecitabine) to Gemzar® (gemcitabine) improves outcomes of patients with advanced or metastatic pancreatic cancer. The details of this study appeared early online October 26, 2009 in the Journal of Clinical Oncology.
Concurrent Chemoradiotherapy Improves Outcomes of Patients with Advanced Head and Neck Cancer (11/2/2009)
Researchers affiliated with the UK Head and Neck (UKHAN1) trial have reported that concurrent chemoradiotherapy reduces recurrences and death in patients with advanced head and neck cancer. The details of this study appeared in an early online publication in Lancet Oncology on October 28, 2009.
Vaccination for HPV in Females Associated with a Decline in Genital Warts in Females and Males (10/29/2009)
Researchers from Australia have reported a decline in the number of cases of genital warts in women and men since the initiation of quadrivalent vaccination to prevent human papillomavirus (HPV) infection. The details of this study appeared in an early on-line publication in Sexually Transmitted Infections on October 16, 2009.
Knowledge Deficits Limit Use of HPV Vaccine in Young Women (10/29/2009)
Researchers from Roswell Park Cancer Institute, Upstate Medical University and the State University of New York at Buffalo have reported that knowledge and risk perceptions among college students limits vaccination for human papillomavirus (HPV). The details of this study appeared in an early on-line publication in Sexually Transmitted Infections on October 19, 2009.
Nexavar® May Reduce Brain Metastases in Patients with Metastatic Renal Cell Carcinoma (10/28/2009)
Researchers from France and Poland have reported that Nexavar® (sorafenib) may reduce the incidence of brain metastases in patients with metastatic renal cell carcinoma (RCC). The details of this study appeared early online on October 22, 2009 in the Annals of Oncology.
HPV Vaccination Not Cost-effective for Women over 30 Years of Age (10/28/2009)
Researchers from the Harvard School of Public Health have reported that human papillomavirus vaccination for prevention of cervical cancer is not cost-effective in women between the ages of 35 and 45 years. The details of this report appeared in the October 20, 2009 issue of the Annals of Internal Medicine.
Long-term Follow-up Validates Effectiveness of Neoadjuvant Chemotherapy for Esophageal Cancer (10/27/2009)
Researchers from the UK have reported that neoadjuvant chemotherapy improves five-year survival from 17.1% to 23.0% in patients with resectable esophageal cancer. The details of this study appeared in the October 20, 2009 issue of the Journal of Clinical Oncology.
More Clinical News »
|
|
|
|
 Member Center |
|
|
 |
Register in our member center today to receive email notification of late breaking cancer news.
Learn More »
|
|
|
|
|
|
|
 Practice Resources |
|
|
 |
Learn how to receive our news headlines on your website.
Learn More »
|
|
|
|
|
|
|
 Links to Information by Cancer Type |
|
|
|
|
|
|
|
|
|
Patient Home
